Original post on mastodon.online

Remember the creation of TrumpRX to supposedly lower drug prices?

All 16 companies released higher list prices for some of their drugs.

Best ROI for companies is a direct bribe to #Trump.
#drugManufacturing #HealthCare […]

Biopharmaceuticals CM Market Global Trends 2035 Biopharmaceuticals Contract Manufacturing Market is reaching at a CAGR of 5.80 %, Expected to Grow from USD 18.82 Billion to USD 34.99 Billion During 2025 - 2035.

Outsourcing trends are fueling rapid expansion in the Biopharmaceuticals Contract Manufacturing Market. Learn more! www.marketresearchfuture.com/reports/biop...
#Biopharma #CDMO #DrugManufacturing

Small Molecule CDMO Market Size, Share, Trends, Report 2035 Small Molecule CDMO Market to grow at 3.66% CAGR, reaching USD 119.98 Billion by 2035, driving, size, growth, global trends, competitive analysis and industry outlook 2025-2035.

Rising outsourcing in drug development is fueling the Small Molecule CDMO Market. Discover emerging opportunities! www.marketresearchfuture.com/reports/smal...
#CDMO #DrugManufacturing #PharmaIndustry

Pharmaceutical Hot Melt Extrusion Market Report, 2035 Pharmaceutical Hot Melt Extrusion Market to grow at 5.89% CAGR, reaching USD 7.49 Billion by 2035, driving, size, growth, global trends, competitive analysis and industry outlook 2025-2035.

⚙️ Advanced drug manufacturing boosts the Pharmaceutical Hot Melt Extrusion Market. Learn more 👉 www.marketresearchfuture.com/reports/phar... #DrugManufacturing

Pharmaceutical Contract Manufacturing Market Report, 2035 Pharmaceutical Contract Manufacturing Market size is expected to grow at a 4.2% CAGR from 2024, 200.92 Billion USD to 315.91 Billion USD by 2035. Pharmaceutical Contract Manufacturing Industry Analysi...

Pharma contract manufacturing boosts scalability & cost efficiency. 👉 www.marketresearchfuture.com/reports/phar... #PharmaCMO #DrugManufacturing

Clopidogrel Production Cost.

Clopidogrel Production Cost insights for better pharma market strategy and sourcing.

Get Your Free Sample Report Today:-www.procurementresource.com/production-cost-report-s...

#ClopidogrelProductionCost #PharmaInsights #DrugManufacturing

FDA’s new guideline expands the use of alternative tools to assess drug manufacturing facilities. Learn how this impacts compliance, quality, and operations: compliancearchitects.com/al...

#FDA #DrugManufacturing #PharmaCompliance #QualitySystems #ComplianceArchitects

India’s drug regulation is stuck in a time warp Calls for tighter government oversight are justified, yet regulation alone may not suffice in a system vulnerable to corruption

In @hindustan-times.bsky.social, OHT’s Dr. Ramanan Laxminarayan highlights the urgent need to strengthen oversight of #DrugManufacturing and ensure #DrugSafety.

Read more: www.hindustantimes.com/opinion/indi...

Here's $MRK absolute computational valuation of 34% undervalued (computed by our "Matrix" engine), plus its relative valuation (where you can see $GILD, $LLY, $BMY, $JNJ, $BIIB, $PFE and $AMGN). #Healthcare and #DrugManufacturing #Finance.

FDA pilots fast-track scheme for US-made generics In another effort to boost domestic drug manufacturing, the FDA is piloting fast-track reviews for generics tested and made in US facilities.

#generics #FDA #pharmamanufacturing #importedmedicines #fasttrackreviews #bioequivalencetesting #APIs #drugmanufacturing #patientaccess #pharmaceuticalmanufacturing #pharmaceuticalproduction #CDER #manufacturingofmedicines #FDAPreCheck #pharmamanufacturingfacilities
zurl.co/yuskn

Active Pharmaceutical Ingredients Market Set to Grow at an Impressive CAGR of 6.9% Through 2032 | USD 299.97 Billion Authenticated data presented in the Active Pharmaceutical Ingredients Market report is based on findings of extensive primary and secondary research

💊 The Active Pharmaceutical Ingredients Market to grow to USD 299.97 Bn by 2032 with 6.9% CAGR. 🔗 www.einpresswire.com/article/7778... #API #PharmaIndustry #DrugManufacturing

Pharmaceutical Hot Melt Extrusion Market Size, Outlook 2035 Pharmaceutical Hot Melt Extrusion Market growth is projected to reach USD 7.5 Billion, at a 5.89% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast rep...

💊 Transforming drug manufacturing with hot melt extrusion tech! Efficient, scalable, & innovative solutions for pharma. 🔥
#HotMeltExtrusion #PharmaTech #DrugManufacturing #HealthcareInnovation

www.marketresearchfuture.com/reports/phar...

Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country. Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%. But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates. Here’s what drugmakers are doing to mitigate supply-chain risks and reassure investors: The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter. Johnson & Johnson The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies’ manufacturing site in Holly Springs, North Carolina, over the next 10 years. Locations for the other plants remain undisclosed. The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years. A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina. CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs. The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas. It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived." The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs. The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company’s sites and partnerships with other domestic manufacturers. Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025. The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March. Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028. CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S. The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina. Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California. Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused". The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade. It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions. Gilead Sciences Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion. Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites. The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York. Most investors will find it hard to answer that question with total confidence. Short of a guarantee, which no one can give you, the most successful traders stick to proven best practices without letting hype or hyper-vigilance take over their better judgment. But that doesn't mean you can't use smart shortcuts. If you're considering LLY, try chatting with WarrenAI, our powerful AI financial assistant. It's just like ChatGPT for investors, but with access to 10 years of company data, a built-in screener, Wall Street analysts' reports, and earnings call transcripts for real-time, vetted insights. Even if you end up going with your gut feeling, at least you'll know why.

Click Subscribe #Pharmaceuticals #DrugManufacturing #USMarket #Tariffs #Healthcare

US Pharmaceutical Manufacturing Equipment Market Report 2032 United States Pharmaceutical Manufacturing Equipment Market is projected to register a CAGR of 6.16% to reach USD 29.79 Billion by the end of 2032, United States Pharmaceutical Manufacturing Equipment...

⚙️💊 Precision, automation & AI are powering the next era of drug production in the US. The pharma factory of the future is here. 🔬
#PharmaTech #DrugManufacturing #HealthcareInnovation

www.marketresearchfuture.com/reports/us-p...

New FDA PreCheck Program to Boost U.S. Drug Manufacturing - OncoDaily New FDA PreCheck Program to Boost U.S. Drug Manufacturing / cancer, FDA PreCheck, Jennifer Buell, MiNK Therapeutics, OncoDaily, Oncology, U.S. Drug

New FDA PreCheck Program to Boost U.S. Drug Manufacturing
@fda.gov

oncodaily.com/insight/fda-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #FDAPreCheck #Drugs #DrugManufacturing

FDA launches PreCheck program to boost domestic drug manufacturing Investing.com -- The U.S. Food and Drug Administration launched a new program called FDA PreCheck on Thursday to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign suppliers. Currently, more than half of pharmaceuticals distributed in the U.S. are manufactured overseas, with only 11% of active pharmaceutical ingredient (API) manufacturers for FDA-approved products based in the United States. "Our gradual overreliance on foreign drug manufacturing has created national security risks," said FDA Commissioner Marty Makary, M.D., M.P.H. "The FDA PreCheck initiative is one of many steps FDA is taking that can help reverse America’s reliance on foreign drug manufacturing and ensure that Americans have a resilient, strong, and domestic drug supply." The program was developed in response to Executive Order 14293, "Regulatory Relief to Promote Domestic Production of Critical Medicines," which directs the FDA to streamline review processes and eliminate unnecessary regulatory requirements. FDA PreCheck introduces a two-phase approach to facilitate new U.S. drug manufacturing facilities. The first phase, called Facility Readiness, provides manufacturers with more frequent FDA communication during facility design, construction, and pre-production stages. Companies are encouraged to submit comprehensive facility information through a Type V Drug Master File. The second phase, Application Submission, focuses on streamlining the Chemistry, Manufacturing, and Controls section of applications through pre-application meetings and early feedback. The FDA will host a public meeting titled "Onshoring Manufacturing of Drugs and Biological Products" on September 30, 2025, at the FDA White Oak Campus in Silver Spring, Maryland. Virtual participation will be available. The meeting will present the FDA PreCheck draft framework and include stakeholder discussions on overcoming onshoring challenges. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

Click Subscribe. #FDA #PreCheck #DrugManufacturing #Healthcare #Pharmaceuticals

Active Pharmaceutical Ingredient Market Expected to Hit USD 234.5 Billion by 2032 with a Remarkable 2.98% CAGR - Industry Today By 2032, the market is expected to grow to USD 234.5 billion at a compound annual growth rate (CAGR) of 2.98% from 2025 to 2032

🧪#API Market forecasted to hit $2.345 T by 2032, expanding at 2.98% CAGR. Backbone of global pharma production meets innovation surge.
#DrugManufacturing #GlobalHealth

industrytoday.co.uk/health_and_s...

Pharmaceutical Equipment Market to Grow to USD 85.0 Billion by 2032, Rising at 4.29% CAGR - Industry Today Pharmaceutical Equipment Market is projected to reach USD 85.0 billion by 2032, growing at a CAGR of 4.29% during the forecast period from 2025 to 2032.

🛠️ Behind Every Pill!
Pharma Equipment Market to grow to $85.0B by 2032 🏭
📊 CAGR: 4.29%

#PharmaMachinery #DrugManufacturing #MedicalTech #EquipmentMarket 🧪⚙️

industrytoday.co.uk/health_and_s...

Record Ground Protection at Pharma Plants Record ground protection at pharma plants: Ensuring ESD control, product quality, and safety through best practices, industry standards, and advanced technologies.

⚡️Why Pharma Needs ESD Protection? 🔬

ESD can wreck sensitive pharma equipment & risk patient safety. Learn how grounding systems prevent disasters in drug manufacturing.

#PharmaSafety #ESDProtection #DrugManufacturing #CleanroomTech #MedTech #PharmaEngineering

His Kidney Failed. He’ll Never Know if a Transplant Drug From a Banned Factory Was to Blame. A heart-wrenching story of a man taking a transplant drug exempted from a ban due to inadequate manufacturing controls. ProPublica reports

His Kidney Failed. He’ll Never Know if a Transplant Drug From a Banned Factory Was to Blame. www.peoplespharmacy.com/articles/his... via @peoplespharmacy

#kidney #kidneytransplant #medication #drugmanufacturing #regulation #oversight #health @propublica.org

Transforming Safety and Efficiency: The Role of Incident Response and Automation Platforms in the Pharmaceutical Industry

💊 Transforming Safety and Efficiency in Pharma

Read the blog here : www.callgoose.com/u/fB

#PharmaSafety #IncidentResponse #CallgooseSQIBS #PharmaceuticalCompliance #AutomationPlatforms #PharmaAutomation #DrugManufacturing #ProcessEfficiency #OperationalExcellence

Global Fill Finish Manufacturing Market Size & Industry Analysis 2031 Fill Finish Manufacturing from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 8.9% from 2024 to 2031.

Explore the latest 📊 Fill Finish Manufacturing Market report for in-depth insights on trends, growth drivers, challenges & key players. Stay ahead in pharma manufacturing! 🌍💉

#Pharmaceuticals #FillFinish #Biotech #MarketResearch #PharmaTrends #DrugManufacturing

‘Namibia lacks capacity to produce malaria drugs’ Namibia currently lacks the capacity to manufacture malaria treatment medication due to high costs and stringent international regulatory requirements. This was confirmed by Fabupharm managing director Fanie Badenhorst, who said the pharmaceutical manufacturer discontinued its malaria drug production several years ago due to ineffectiveness and financial limitations. “The chloroquine product that we used to manufacture is an old molecule which malaria parasites have become resistant to, so it was no longer effective. That is why it was discontinued,” he said in an interview yesterday. “At this stage, we do not have any malaria products that we manufacture or import.” According to Badenhorst, malaria treatments must meet World Health Organisation (WHO) pre-qualification standards, a costly and complex process that Namibia is currently unable to finance. “To register and manufacture WHO-approved malaria drugs requires extensive data, clinical trials and certification. It is very expensive, and at this stage, we simply cannot afford it,” he said. PROFITEERING The disclosure comes amid growing public scrutiny over how Namibia sources its malaria medication during a national outbreak, with over 76 195 confirmed cases and 132 deaths reported between December 2024 and 20 May 2025. Affirmative Repositioning (AR) leader and parliamentarian Job Amupanda has accused Ministry of Health and Social Services officials and middlemen of profiteering from government medical procurements. In a social media post on Sunday, Amupanda claimed his investigation team, Eagle 25, intercepted a consignment of malaria tablets last week that entered Namibia through the Ngoma border post. He alleged that the government paid N$1 500 per pack of 100 tablets, totalling N$450 000 for 300 packs, while the supplier’s invoice showed a price of only N$580 per pack. “The middlemen only paid N$175 000 in total, and they made a clean N$275 000 from this single product,” Amupanda said, and added that even if transportation costs were factored in at N$50 000, the middlemen would still have pocketed N$225 000. He further claimed the specific tablets procured were no longer recommended due to adverse side effects, but were still being bought using public funds. “This is how rallies of the corrupt are funded. This is how pockets are lubricated,” he wrote. EMERGENCY MEASURES Health ministry spokesperson Walters Kamaya in a statement denied allegations of corruption over the emergency procurement of malaria treatment tablets. He said the purchase was made under emergency provisions of the Public Procurement Act to prevent treatment interruptions and potential loss of life. “While Artemether-Lumefantrine remains the first-line treatment for uncomplicated malaria, quinine remains a vital second-line treatment, particularly for pregnant women and patients who react negatively to first-line drugs,” the ministry said. The ministry further stated that the selected supplier, West Pharmaceuticals, was able to deliver the urgently-needed drugs within a week, which was a critical factor during the escalating outbreak. In the statement, Kamaya said direct procurement from manufacturers was not viable, as their minimum order requirement was 60 000 packs, far more than the ministry’s emergency request of 300 packs. “No payment has been made to the supplier and the consignment has been quarantined while import documentation is verified in collaboration with the Namibia Revenue Agency. A comprehensive internal review is underway,” the ministry spokesperson said. Kamaya further noted that medicine prices are often affected by global supply and demand, and that during disease outbreaks prices for life-saving drugs tend to increase. The post ‘Namibia lacks capacity to produce malaria drugs’ appeared first on The Namibian.

#Malaria #Namibia #Healthcare #Pharmaceuticals #DrugManufacturing

HHS, DARPA link up with Rutgers, Cost Plus Drugs and others in initiative to rethink US drug production On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts to boost medicine manufacturing in the U.S. | In a new public-private partnership,...

New public-private partnership "Equip-A-Pharma" aims to improve manufacturing of 8 essential medicines in the US. HHS/DARPA working with universities and companies to use AI and advanced tech to address drug shortages and lower costs. #DrugManufacturing #MedicationAccess

Risk Matters: Tariff Risks and Opportunities for Pharma Manufacturers
www.newswise.com/articles/ris...
#riskmanagement#PharmaceuticalBusiness #PharmaceuticalManufacturing #tariffs #ContinuousManufacturing #drugmanufacturing

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. The Food and Drug Administration found issues at an Indian factory making generic drugs linked to deaths. #FDA #DrugRecalls #MedicationSafety #HealthCare #DrugManufacturing #FDAInspections

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems.

The Food and Drug Administration found issues at an Indian factory making generic drugs linked to deaths. #FDA #DrugRecalls #MedicationSafety #HealthCare #DrugManufacturing #FDAInspections

Making ibuprofen work better with grinding Researchers have found a simple, environmentally friendly way to make a more effective form of ibuprofen. The technique, which uses a ball mill, could help manufacturers to lower their energy and material...

Making ibuprofen work better with grinding #Science #Chemistry #Pharmaceuticals #Ibuprofen #BallMill #DrugManufacturing

Celltrion wins approval for allergic asthma treatment biosimilar in Canada - Yes Punjab News South Korea's Celltrion has received approval from Health Canada for its biosimilar treatment, Omlyclo, for allergic asthma. The company plans to expand its presence in Canada, with a third manufactur...

Celltrion wins approval for allergic asthma treatment biosimilar in Canada
yespunjab.com?p=71183

#Celltrion #BiosimilarTreatment #Asthma #Omlyclo #Xolair #HealthCanada #PharmaceuticalIndustry #Biosimilar #DrugManufacturing #Canada